BidaskClub Lowers Amarin Corporation PLC (AMRN) to Buy

Three analysts have issued estimates for Amarin Corporation PLC's earnings, with the highest EPS estimate coming in at ($0.04) and the lowest estimate coming in at ($0.06). During the same period past year, the business posted ($0.07) earnings per share. It has Quarterly performance and year to date performance of 7.95% and 5.84% respectively. UBS Group AG boosted its position in Amarin Corporation PLC by 7.4% in the first quarter. For the next fiscal year, analysts expect that the business will post earnings of $0.01 per share, with EPS estimates ranging from ($0.11) to $0.24. AMRN was included in 9 notes of analysts from May 12, 2016. The Return on Investment (ROI) ratio of Amarin Corporation plc (AMRN) is -91.1 percent. Comparatively, AMRN posted earnings of $0 per share in the same quarter, a year earlier. The company had revenue of $44.95 million for the quarter, compared to analyst estimates of $40.35 million. Amarin Corporation PLC's revenue for the quarter was up 37.0% on a year-over-year basis. Polaris Greystone Fincl Group Ltd Limited Liability Company has invested 0.01% in Amarin Corporation plc (ADR) (NASDAQ:AMRN).

BidaskClub downgraded shares of Amarin Corporation PLC (NASDAQ:AMRN) from a hold rating to a sell rating in a report issued on Friday morning. Citigroup initiated Amarin Corporation plc (ADR) (NASDAQ:AMRN) on Wednesday, October 19 with "Buy" rating. HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Amarin Corporation PLC in a research report on Thursday, June 1st. Finally, Cantor Fitzgerald set a $5.00 price target on shares of Amarin Corporation PLC and gave the company a "buy" rating in a research report on Monday, June 12th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. Also, the current price highlights a discount of 212.5% to analysts' high consensus price target.

Amarin Corporation plc (NASDAQ:AMRN) stock has moved in a downward direction this week, causing concern for some investors.

The counter witnessed a trading volume of 2.63 million shares versus an average volume of 2.42 million shares during last trading session. Fmr Ltd holds 0% of its portfolio in Amarin Corporation plc (ADR) (NASDAQ:AMRN) for 2.04M shares. The share price has moved backward from its 20 days moving average, trading at a distance of -25.14% and stays -22.14% away from its 50 days moving average. The firm's market cap is $912.59 million.

Alvaro Morata scores his first goal for Chelsea in defeat to Burnley
To take over a team 11th in the top flight the year before and comfortably win the title was a fantastic achievement. Champions Chelsea struggled in the Community Shield last weekend as they were beaten on penalties by Arsenal .

In other Amarin Co. plc news, General Counsel Joseph T. Kennedy sold 307,911 shares of the firm's stock in a transaction that occurred on Monday, July 3rd. They now have a United States dollars 1.5 price target on the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The stock had previously closed at $3.29, but opened at $3.57. Quantitative Investment Management LLC raised its position in shares of Amarin Corporation PLC by 105.1% in the first quarter. California Public Employees Retirement System now owns 533,300 shares of the biopharmaceutical company's stock valued at $1,707,000 after buying an additional 62,800 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of Amarin Corporation PLC by 0.9% in the first quarter. Renaissance Technologies LLC boosted its position in Amarin Corporation PLC by 348.2% in the first quarter. JPMorgan Chase & Co. now owns 278,134 shares of the biopharmaceutical company's stock valued at $1,121,000 after buying an additional 242,544 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Amarin Corporation PLC by 662.8% in the fourth quarter. The firm owned 422,549 shares of the biopharmaceutical company's stock after selling 210,385 shares during the period. Hedge funds and other institutional investors own 37.57% of the company's stock.

TRADEMARK VIOLATION WARNING: "Amarin Corporation PLC (AMRN) Stake Cut by Goldman Sachs Group Inc." was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another publication, it was illegally copied and republished in violation of United States & global copyright and trademark law.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health.

Latest News